Skip directly to site content Skip directly to page options Skip directly to A-Z link Skip directly to A-Z link Skip directly to A-Z link
Volume 30, Number 7—July 2024
Dispatch

Reemergence of Clade IIb–Associated Mpox, Germany, July–December 2023

Patrick E. ObermeierComments to Author , Clarissa F. Plinke, Annika Brinkmann, Raskit Lachmann, Julia Melchert, Victor M. Corman, Andreas Nitsche, Ulrich Marcus, Axel J. Schmidt, Klaus Jansen, and Susanne C. Buder
Author affiliations: Vaccine Safety Initiative, Berlin, Germany (P.E. Obermeier); Vivantes Hospital Neukölln, Berlin (C.F. Plinke, S.C. Buder); Robert Koch-Institute, Berlin (A. Brinkmann, R. Lachmann, A. Nitsche, U. Marcus, K. Jansen); Charité–Universitätsmedizin Berlin and Berlin Institute of Health, Berlin (J. Melchert, V.M. Corman); London School of Hygiene and Tropical Medicine, London, UK (A.J. Schmidt)

Main Article

Figure 2

Number of clade II–associated mpox cases in Germany, July–December 2023, by federal state and reporting week (weeks 30–52). Total number of cases was 110.

Figure 2. Number of clade II–associated mpox cases in Germany, July–December 2023, by federal state and reporting week (weeks 30–52). Total number of cases was 110.

Main Article

Page created: May 14, 2024
Page updated: June 22, 2024
Page reviewed: June 22, 2024
The conclusions, findings, and opinions expressed by authors contributing to this journal do not necessarily reflect the official position of the U.S. Department of Health and Human Services, the Public Health Service, the Centers for Disease Control and Prevention, or the authors' affiliated institutions. Use of trade names is for identification only and does not imply endorsement by any of the groups named above.
file_external